

Peter Pauwels, Ph.D.

☎ +33.474.33.23.77

✉ peter.pauwels@dap-sante.fr

☎ +33.647.93.59.46

PROFILE

Senior consultant in Research & Development of Oncology. Background consists of research management with international experience in drug discovery in the Pharmaceutical/Biotechnology sectors. Proven skills in the discovery and Proof of Concept of innovative therapeutics for the treatment of Cancer and Central Nervous System disorders. Capability to restructure and focus research organizations. Confirmed experience in management of partnering in research and innovation in complex institutional environments. Knowledge to enhance the efficacy of clinical and industrial transfer issued from public research.

Coordination of Cancer Network Organization

- ✓ Development of the French cancer research network organization CLARA within the Rhône-Alps-Auvergne regions to intensify cooperation between different research institutions (including university and anti-cancer hospitals) and industrial partners with emphasis on translational oncology research, technology transfer and economic development.
- ✓ Constructed, launched and managed on demand of the French National Institute of Cancer, both in 2007 and 2011, a 3-year strategic plan for CLARA by taking into account the recommendations of the French national Cancer Plans I and II.
- ✓ Built and supervised a Proof of Concept project portfolio with 30 innovative projects as based on public-private partnerships. One product (Viky mini-robot for laparoscopic surgery) on European and American markets, 4 projects in clinical development and 3 nanomedicine projects obtained preclinical proof of concept.

Management of Research Activities

- ✓ Restructured biological/pharmacological activities at *Esteve Laboratories* (Barcelona, Spain) in 2005 to advance research productivity towards therapeutics against Obesity and Pain.
- ✓ Reorganized, focused and established a Drug Discovery Research Plan at *Centre d'Immunologie Pierre Fabre* (Saint-Julien-en-Genevois, France) in 2002 for innovative biologicals in the field of Oncology.
- ✓ Key-member of special assignment integration team in 1999-2000 for scientific interface between two independent R&D organizations - *Pierre Fabre* and *bioMérieux* - constructing a common oncology research program on theranostics.

Leading Drug Discovery Research into Innovative Therapeutic Solutions

- ✓ Discovered several unique compounds at *Esteve Laboratories* (Barcelona) which induce hypophagia, profound and sustained weight loss in pre-clinical models with better efficacy than the Reference treatment sibutramine.
- ✓ Conducted a successful search at *Centre d'Immunologie Pierre Fabre* (Saint-Julien-en-Genevois) to licence-out its first growth factor receptor antibody for development in cancer treatment to Merck & Co.
- ✓ Key-member of team developing at *Centre de Recherche Pierre Fabre* (Castres, France) original compounds for Central Nervous System disorders.
- ✓ Within *Pierre Fabre*, compiled 110 scientific publications between 1992 and 2002, including both major Reviews and Pharmacology papers related to original compounds in drug discovery.

PROFESSIONAL EXPERIENCE

NH-TherAguix, Lyon, France

2018 - ongoing

Pharma Business Development

NH-TherAguix is focused on enhancement of radiotherapeutic efficacy in solid tumors by theranostic nanodrugs. Phase 1 clinical trial with lead compound in multiple cerebral metastases is almost finished. Three Phase 2 trials are programmed.

DAP-Santé Consulting, Rhône-Alps, France

2013 - ongoing

Senior consultant to promote the Development of Applications for Oncology Projects related to **Healthcare** and based on combined expertise in Drug Discovery, Pharma/Biotech R&D, Research Partnering and Societal Impact (<http://dap-sante.fr/who.htm>).

Curadev Pharma Private Limited, New Delhi, India

2010 - 2017

Scientific adviser

Curadev has recently entered into a research collaboration and exclusive license agreement with Roche for the development and commercialization of IDO1 (indoleamine-2, 3-dioxygenase-1) and TDO (tryptophan-2, 3-dioxygenase) inhibitors to develop cancer immunotherapeutics.

Ecrins Therapeutics, Grenoble, France

2010 - 2016

Member strategic advisory board

First-in-Class small molecule for cancer therapy with an original anti-vascular and anti-proliferative mechanism of action. The company aims to develop its drug candidates to clinical Proof of Concept.

Cancéropôle Lyon Auvergne Rhône-Alps (CLARA), France

2006 - 2013

Executive Director CLARA, Lyon (September 2007-January 2013)

Director of Programs and Industrial Development, Lyon (September 2006-August 2007)

In charge of facilitating and strengthening the coordination of cancer research within the French Rhône-Alps-Auvergne inter-region with emphasis on integration and cooperation of different research institutions, university & anti-cancer hospitals, and industrial partners to

yield more rapidly innovation and make progress more accessible. Major goals: promotion of scientific excellence, development of multidisciplinary oncology research and economic development by public-private partnerships. Fund raising obtained from European Regional Development Funds, French National Institute of Cancer, local authorities and industrial partners. CLARA has been positively evaluated by AERES (French national Evaluation Agency for Research and Higher Education) and certified by the National Institute of Cancer in March 2011.

Laboratorios Dr. Esteve, Barcelone, Spain

2004 - 2006

Director Biological Discovery Research, Barcelona

Responsible for managing biological discovery research in order to guide research projects towards innovative therapeutic small chemical compounds in CNS and Metabolic Disorders. Also responsible for external collaboration contracts and in charge of research communication strategy. Member of Research Board and Late Discovery Board.

Laboratoire Pierre Fabre, France

1992 - 2004

Managing Director Centre d'Immunologie Pierre Fabre, St-Julien-en-Genevois (2002-2004)

Managed staff of 120 working in six departments with an annual budget of 13 M€. Specific duties included scientific management aimed at generating Cancer research projects to discover innovative biopharmaceuticals such as antibodies.

Deputy Director Centre de Recherche Pierre Fabre (CRPF), Castres (1998-2002)

Supervised Pharmacological Research Projects with small chemical compounds in Central Nervous System (CNS), Cardiovascular Diseases and Oncology. Also established a three year plan in 2000 on research objectives, strategies and investment for a staff of 220 and an annual budget of 21 M€.

Director Cellular & Molecular Biology Department CRPF, Castres (1992-2002)

Over a period of ten years, took increasing responsibility for highly effective, cutting-edge underpinning at the levels of molecular and cellular biology of discovery research projects in CNS, Cardiovascular Diseases and Oncology.

Janssen Pharmaceutica, Belgium

1984 - 1992

Senior Research Scientist Biochemical Pharmacology Department, Janssen Research Foundation, Beerse (1987-1992).

Scientist Biochemical Pharmacology Department, Janssen Research Foundation, (1984-1987).

ACADEMIC ACTIVITIES

- (co)-author of >170 scientific publications:
https://www.researchgate.net/profile/Petrus_Pauwels2/contributions
- *Centre National de la Recherche Scientifique (CNRS)* : Appointed Member Section 22 *Thérapeutique et Médicaments: Concepts et Moyens*, Paris, 1999.
- University Paul Sabatier Toulouse III (France): in charge of students of 3rd cycle, 1992-2002, and Member of Council: *Diplome d'Etudes Approfondies de Pharmacologie Moléculaire & Cellulaire*, 1994-2002
- Editorial board member of *Journal of Pharmacological and Toxicological Methods*.

EDUCATIONAL HIGHLIGHTS

- Ministry of National Education, Research and Technology (Paris): qualified with *Prof. Degree* in Neuroscience, 2000.
- International Institute of Cellular and Molecular Pathology (Nobel Price Prof. C. de Duve & Prof. Dr. A. Trouet, Brussels) and University of Ghent (Prof. Dr. W. Fiers): *Ph.D. Degree* in Cellular & Molecular Pathology, 1984.
- University of Ghent, Belgium: *M.Sc. Degree* Biology: Biochemistry-Physiology specialization, 1974-1978.

PERSONAL INFORMATION

Nationality Belgium
 Languages Dutch: mother tongue, French and English: fluent, Spanish and German: basic